1. M. CHRISTOPHER ROEBUCKRxEconomics LLC 11350 McCormick Road, Suite 705 Hunt Valley, MD 21031(410) 215-8380 www.RxEconomics.com mcr@rxeconomics.com SUMMARYHealth Economist with over 15 years of experience in pharmacoeconomics and health services/outcomes research. Detail-orientedcritical thinker who successfully leverages extensive education, advanced quantitative skills, and rich healthcare background to deriveempirical answers to important business and societal questions. Adept at operating at the nexus of academia and private industry,routinely publishing in high-quality journals, and speaking publically on topics of expertise. Core competencies lend strength to: Pharmacy benefit design and optimization Comparative effectiveness research Economic evaluation of health care programs Health policy and legislation analysis Predictive modeling of health services use and cost Applied econometrics, statistics, and analytics Medical/prescription claims data coding and analysis Translation of scientific research into business practicePROFESSIONAL EXPERIENCERXECONOMICS LLC, Hunt Valley, MD2010-PresentPrincipal, Health Economist Provide expert, applied health economics research consulting services to healthcare providers, payers, and policymakers. Apply econometric methods in analyzing claims data to answer critical business questions, bolster value propositions; and gaininsight into the impact of pharmacy benefit design on prescription drug use, and the medical cost savings and productivityenhancements derived from medication adherence. Advise clients on issues of healthcare reform, value-based insurance design and purchasing.CVS CAREMARK, Hunt Valley, MD2002-2011Director, Strategic Research-Health Economist (2007-2011) Led analytics team in the design and production of health economics and outcomes research studies including the evaluation ofpharmacy benefit management products and services, as well as the comparative effectiveness of pharmacotherapies. Advanced the science of pharmacy benefit design, Medicare Part D plan choice, and the value of medication adherence. Rendered advanced statistics and econometrics methodological coaching and oversight companywide. Conducted health policy analysis of legislation and advised executive leadership on expected economic impacts. Disseminated findings via top-tier, peer-reviewed journal publication and presentation at industry conferences. Coordinated collaborations with external academic, plan sponsor, and manufacturer partners.Manager, Predictive Modeling and Forecasting (2005-2007) Built and optimized claims-based predictive models of health services use and cost, also used for risk adjustment. Employed time-series, data mining, and Monte Carlo simulation methods for forecasting of key business metrics.Consulting Research Analyst (2002-2005) Constructed budget impact models of new brand and generic drug launches for plan sponsor customers. Designed, sold, executed, and delivered pharmacoeconomics and outcomes research studies to manufacturer clients. Managed product that calculated the script-lift and return-on-investment of direct-to-consumer advertising campaigns.UNIVERSITY OF MIAMI, SCHOOL OF MEDICINE, Miami, FL1998-2002Senior Research Associate Performed economic evaluations of public and private substance abuse and mental health treatment programs using the DrugAbuse Treatment Cost Analysis Program, Addiction Severity Index, and Treatment Services Review. Investigated relationships between substance abuse and health, criminal activity, employment, and education using advancedeconometric techniques in the analysis of various public use datasets. Served as Project Director of four multi-year grants totaling approximately $1 million sponsored by the National Institute onDrug Abuse, Center for Substance Abuse Treatment, and Robert Wood Johnson Foundation. EDUCATIONDoctor of Philosophy Candidate, Public Policy, UMBC, Baltimore, MD, expected 2012.Master of Business Administration, Finance, University of Miami, Coral Gables, FL, 1997.Bachelor of Arts, Economics, University of Pennsylvania, Philadelphia, PA, 1994.TECHNICAL SKILLSEconometrics: endogeneity testing and control using panel data methods, instrumental variables, and propensity score matching.Software: STATA (expert), SAS, SPSS, @Risk.

2. M. Christopher RoebuckPage 2 of 2SELECTED PUBLICATIONSKetcham, J., C. Lucarelli, E. Miravete, and M.C. Roebuck. In Press. Sinking, Swimming, or Learning to Swim in Medicare Part D.American Economic Review.Carls, G.S., M.C. Roebuck, T.A. Brennan, J.A. Slezak, O.S. Matlin, and T.B. Gibson. 2012. Impact of Medication Adherence onAbsenteeism and Short-Term Disability for Five Chronic Diseases. Journal of Occupational and Environmental Medicine 54(7):792-805.Polinski, J.M., W.H. Shrank, R.J. Glynn, H.A. Huskamp, M.C. Roebuck, and S. Schneeweiss. 2012. Beneficiaries with Cardiovascular Disease and the Part D Coverage Gap. Circulation: Cardiovascular Quality and Outcomes 5: 387-395.Roebuck, M.C., J.N. Liberman, M. Gemmill-Toyama, and T.A. Brennan. 2011. Medication Adherence Leads to Lower Health Care Use and Costs Despite Increased Drug Spending. Health Affairs 30(1):91-99.Liberman, J.N. and M.C. Roebuck. 2010. Prescription Drug Costs and the Generic Dispensing Ratio. Journal of Managed CarePharmacy 16(7): 502-506.Roebuck, M.C. and J.N. Liberman. 2009. Impact of Pharmacy Benefit Design on Prescription Drug Utilization: A Fixed Effects Analysis of Plan Sponsor Data. Health Services Research 44(3): 988-1009.Knealing, T.W., M.C. Roebuck, C.J. Wong, and K. Silverman. 2008. Economic Cost of the Therapeutic Workplace Intervention Added to Methadone Maintenance. Journal of Substance Abuse Treatment 34(3): 326-332.Powers, C.A., C.M. Meyer, M.C. Roebuck, and B. Vaziri. 2005. Predictive Modeling of Total Healthcare Costs Using Pharmacy Claims Data: A Comparison of Alternative Econometric Cost Modeling Techniques. Medical Care 43(11): 1065-1072.French, M.T., M.C. Roebuck, and P.K. Alexandre. 2004. To Test or Not to Test: Do Workplace Drug Testing Programs ReallyDiscourage Employee Drug Use?" Social Science Research 33(1): 45-63.Roebuck, M.C., M.T. French, and M.L. Dennis. 2004. Adolescent Marijuana Use and School Attendance. Economics of Education Review 23(2): 145-153.Roebuck, M.C., M.T. French, and A.T. McLellan. 2003. DATStats: Results from 85 Studies Using the Drug Abuse Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment 25(1): 51-57.French, M.T., M.C. Roebuck, and P.K. Alexandre. 2001. Illicit Drug Use, Employment, and Labor Force Participation." SouthernEconomic Journal 68(2): 349-368.SELECTED PRESENTATIONSRoebuck, M.C., G.S. Carls, T.B. Gibson, J.A. Slezak, J.N. Liberman, and T.A. Brennan. Impact of Medication Adherence on Worker Productivity: An Instrumental Variables Analysis of Five Chronic Diseases. Presented at Academy Health Annual Research Meeting, Seattle, WA, June 13, 2011.Roebuck, M.C. and T.B. Gibson. Measurement and Modeling Issues with Adherence to Pharmacotherapy. Presented at Academy of Managed Care Pharmacy Educational Conference, St. Louis, MO, October 14, 2010.Roebuck, M.C., J.N. Liberman, M. Gemmill-Toyama, and T.A. Brennan. Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Models of Health Services Utilization and Cost. Presented at Biennial Conference of American Society of Health Economists, Cornell University, Ithaca, NY, June 21, 2010.Roebuck, M.C., D. Esposito, M.W. Lewis, and J. Berger. Dollars to Doughnuts: Predicting Prescription Drug Costs of Enrollees and the Medicare Program under Part D. Presented at Academy Health Annual Research Meeting, Seattle, WA, June 26, 2006. Received Best Abstract Award (out of 1,670 presentations).PROFESSIONAL AFFILIATIONSMember of: Academy Health, American Economic Peer Reviewer for: Health Affairs, Health Services Research,Association, American Society of Health Economists Journal of Drug Issues, Journal of General Internal Medicine,(Scientific Committee Member), International HealthJournal of Managed Care Pharmacy (Editorial AdvisoryEconomics Association (Scientific Committee Member), Board Member), Journal of Substance Abuse Treatment.Intl Society for Pharmacoeconomics & Outcomes Research